Terufumi Kato
- Oncology top 0.2%
- Lung Cancer Research Studies 66
- Colorectal Cancer Treatments and Studies 62
- Cancer Immunotherapy and Biomarkers 58
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations 190
- Lung Cancer Diagnosis and Treatment 70
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 36
- Gastric Cancer Management and Outcomes 21
- Cancer Research top 1%
- Cancer Genomics and Diagnostics 28
- Molecular Biology top 5%
- Epidemiology top 5%
Terufumi Kato
262 papers receiving 8.5k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 5.9k
- Pulmonary and Respiratory Medicine 6.6k
- Cancer Research 1.2k
- Molecular Biology 1.9k
- Epidemiology 599
Countries citing papers authored by Terufumi Kato
This map shows the geographic impact of Terufumi Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terufumi Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terufumi Kato more than expected).
Fields of papers citing papers by Terufumi Kato
This network shows the impact of papers produced by Terufumi Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terufumi Kato. The network helps show where Terufumi Kato may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Terufumi Kato, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 7 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 15 | |
| 7 | 2024 | 0 | |
| 8 | 2024 | 5 | |
| 9 | 2023 | 11 | |
| 10 | 2023 | 16 | |
| 11 | 2023 | 0 | |
| 12 | 2022 | 6 | |
| 13 | 2022 | 23 | |
| 14 | 2021 | 15 | |
| 15 | 2021 | 0 | |
| 16 | 2020 | 10 | |
| 17 | 2020 | 9 | |
| 18 | 2019 | 124 | |
| 19 | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studybreakdown → | 2014 | 561 |
| 20 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutationsbreakdown → | 2013 | 2461 |
About Terufumi Kato
Terufumi Kato is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 277 papers that have together received 8.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (190 papers), Lung Cancer Diagnosis and Treatment (70 papers), Lung Cancer Research Studies (66 papers), Colorectal Cancer Treatments and Studies (62 papers), Cancer Immunotherapy and Biomarkers (58 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (36 papers), Cancer Genomics and Diagnostics (28 papers) and Gastric Cancer Management and Outcomes (21 papers). The work is most often cited by research in Oncology (5.9k citations), Pulmonary and Respiratory Medicine (6.6k citations) and Cancer Research (1.2k citations). Terufumi Kato has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Nobuyuki Yamamoto, James Chih‐Hsin Yang, Ki Hyeong Lee, Wu‐Chou Su, Dan Massey, Martin Schüler, Tony Mok, Jaafar Bennouna, Kenneth J. O’Byrne and Chun‐Ming Tsai. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.